Last edition
News about "pharmacokinetics (PK)"
Pin Therapeutics Administers First Dose of PIN-5018 in Adenoid Cystic Carcinoma Patient
Pin Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation, has begun dosing in a Phase 1 clinical trial evaluating its CK1α-selective degrader, PIN-5018. The first patient enrolled in the study has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.
Pharmacokinetics (PK) | 24/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members